CN106943392A - A kind of medical composition and its use for being used to treat children's hernia - Google Patents

Abstract

The invention relates to a pharmaceutical composition for treating hernia in children and its use. The pharmaceutical composition includes p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid, local anesthetic and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition of the present invention After being applied locally or injected into the hernia sac, it can stimulate the non-bacterial inflammatory response of the hernia ring, promote the proliferation of fibroblasts, induce fibrosis of the tissue around the hernia ring, promote tissue repair, and gradually shrink the hernia ring. until closed. The medicinal composition of the present invention is safe and effective when used locally, does not require surgery, and can avoid the pain caused by surgery.

Description

A kind of pharmaceutical composition for treating hernia in children and its application

technical field

The invention belongs to the field of medicines, and in particular relates to a medicine composition for treating children's hernia and its application.

Background technique

Infantile hernia is one of the common diseases in children, mainly including indirect inguinal hernia, umbilical hernia, etc. The formation of hernia is related to factors such as weak normal tissue strength and increased intra-abdominal pressure. If it is large, it can cause intestinal necrosis, etc., and in severe cases, it can endanger the life of the child. There are congenital and acquired factors in the formation of hernia in children. The congenital factors are mainly congenital physiological defects, and the acquired defects include acquired malnutrition. The child's sudden crying leads to a sudden increase in abdominal pressure, and the contents of the abdominal cavity break through the weak link. Protruding outwards forms various types of hernias, which have a serious impact on children's growth and development.

When the child is under one year old, the hernia may still heal on its own. When the child is over one year old, it is generally difficult to heal by itself, and timely treatment is required. The current clinical methods for treating hernia mainly include:

Surgical therapy: After the child is under general anesthesia, the hernia sac is ligated at a high position to prevent the contents of the hernia from protruding, to strengthen the repair of the anterior or posterior wall of the spermatic cord, and to enhance the tension and strength of the abdominal wall. Surgical treatment is currently one of the most effective treatments for hernia in children, but it also has many disadvantages: (1) the wound caused by the operation and the possible wound infection in the later period bring great pain to the child; (2) there are repeated (3) The child needs to be given general anesthesia, and there are adverse reactions such as postoperative restlessness.

Hernia belt: This method has a certain effect on newborn babies, but the effect on children over 1 year old is very poor, and it is almost ineffective for children over 2 years old.

Medication: At present, most of the drug treatments for hernia in children are Fangfeng, Ephedra, Hawthorn, Angelica and other drug prescriptions, and the therapeutic effect is poor. There is also a method for treating hernia in children by local injection of sclerosing agent at present, but the therapeutic effect is not ideal, and there are many side effects.

In order to overcome various disadvantages of the existing methods for treating hernia in children, the present invention is committed to developing a safe and effective pharmaceutical composition for treating hernia in children.

Contents of the invention

One object of the present invention is to provide a pharmaceutical composition for treating hernia in children, which comprises p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid, local anesthetic and pharmaceutically acceptable auxiliary materials.

Preferably, the weight ratio of p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid and local anesthetic in the pharmaceutical composition for treating hernia in children is 1-5:5-10:1-5:0.5-2, preferably 2 -3:6-8:1-2:0.5-1, more preferably 3:8:1:0.5.

Preferably, the local anesthetic is selected from lidocaine, procaine, bupivacaine or ropivacaine, more preferably lidocaine.

The invention provides a pharmaceutical composition for treating hernia in children, which comprises 3 parts of p-hydroxybenzonitrile, 8 parts of proanthocyanidin, 1 part of chlorogenic acid, 0.5 part of lidocaine and pharmaceutically acceptable auxiliary materials.

The pharmaceutical composition for treating hernia in children of the present invention is suitable for local use or injection in hernia sac, suitable local preparations include ointment, spray, etc., preferably ointment, and suitable injection preparations are injection or freeze-dried powder injection. The pharmaceutical composition for treating hernia in children according to the present invention can be prepared into corresponding dosage forms using conventional preparation methods in the art

Preferably, the topical formulation of the present invention further comprises a penetration enhancer, more preferably, the penetration enhancer is urea.

The content of the active ingredients p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid and local anesthetic in the pharmaceutical composition for treating hernia in children according to the present invention can be 1-90% of the total weight of the pharmaceutical composition, preferably 5-30%, More preferred is 10-20%, most preferred is 15%.

Another object of the present invention is to provide the application of the combination of p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid and local anesthetic in the preparation of a pharmaceutical composition for treating hernia in children.

Preferably, the local anesthetic is selected from lidocaine, procaine, bupivacaine or ropivacaine, more preferably lidocaine.

The weight ratio of p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid and local anesthetic in the pharmaceutical composition for treating hernia in children is 1-5:5-10:1-5:0.5-2, preferably 2-3: 6-8:1-2:0.5-1, more preferably 3:8:1:0.5.

Beneficial effect

The pharmaceutical composition for treating hernia in children of the present invention can effectively treat hernia in children without surgery, is safe and effective, and the patient has no pain. It can promote the proliferation of fibroblasts, induce fibrosis of the tissue around the hernia ring, promote tissue repair, and gradually shrink the hernia ring until it is closed, thus effectively treating hernia in children.

detailed description

Hereinafter, the present invention is described in more detail to facilitate understanding of the present invention.

It should be understood that the terms or words used in the specification and claims should not be understood as having the meaning defined in the dictionary, but should be understood as having the meaning consistent with the meaning in the context of the present invention on the basis of the following principles Meaning: The concepts of the terms may be appropriately defined by the inventor for the best description of the invention.

Embodiment 1: a kind of ointment for treating hernia in children

p-Hydroxyphenylacetonitrile 30g;

Proanthocyanidins 80g;

Chlorogenic acid 10g;

Lidocaine 5g;

Urea 15g;

Methylparaben 5g;

Vaseline 855g;

The ointment for the treatment of children's hernia is prepared through the following steps:

(1) Take p-hydroxyphenylacetonitrile, proanthocyanidins, chlorogenic acid, lidocaine, urea, methylparaben and vaseline according to the formula quantity;

(2) Add hydroxyphenylacetonitrile, proanthocyanidins, chlorogenic acid, lidocaine, urea, methylparaben and 200g vaseline into the batching tank and stir evenly;

(3) Stir evenly after adding the remaining vaseline, fill it after sterilization, and obtain the ointment for treating hernia in children of the present invention.

Effect example 1: Effect on incisional hernia of abdominal wall in rats

1.1 Experimental drugs

(1) the ointment of embodiment 1 treatment infantile hernia.

1.2 Experimental method

15 4-week-old male SD rats, weighing 75±5g.

After 2 days of adaptive feeding, the rats had free access to water, but were fasted for 12 hours, anesthetized with 3% pentobarbital intraperitoneally, fixed on the operating table, and a 3×3cm area was drawn with the lower abdomen of the rat as the center line for hair removal , and successively disinfected with iodine and 75% alcohol, cut the skin longitudinally along the center of the rat’s abdomen in the depilatory area, with a length of about 3 cm. Disinfected every day, 7 days later, 10 rats with hernia sac formed were selected and randomly divided into two groups, specifically the blank group and Example 1 group, and the length and width of the hernia sac were measured in each group. Apply the experimental drug to the hernia sac and surrounding skin twice a day, wherein the blank group is smeared with the same ointment as in Example 1, but does not contain ointment of p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid, and lidocaine. The administration was continued for 30 days, and 3 hours after the last administration, the rats were anesthetized again, the length and width of the hernia sac were measured, the hernia ring was exposed, and the inner diameter of the hernia ring was measured in each group of rats. The specific experimental results are shown in Table 1.

1.3 Test results

Table 1. Effects on rat abdominal incisional hernia

Note: Compared with blank group: **P<0.01.

The experimental results of incisional hernia in the abdominal wall of rats showed that the size of the hernia sac increased significantly after 30 days of feeding in the blank group rats with the increase of body weight, while the rats using the ointment of Example 1 of the present invention had a significant increase in body weight. However, the size of the hernia sac not only did not increase, but the size of the hernia sac decreased to a certain extent compared with that before administration, and after applying the ointment of the first group of the embodiment of the present invention, the diameter of the hernia ring of the rat abdominal wall incisional hernia was also obvious. smaller than the blank group, thus showing that the ointment of Example 1 of the present invention has an excellent effect of treating hernia.

Effect example 2: Effect on the proliferation of mouse skin fibroblasts (3T6)

2.1 Experimental drugs

Weigh p-hydroxyphenylacetonitrile, proanthocyanidins, chlorogenic acid, and lidocaine according to the ratio of 3:8:1:0.5, and use PBS solution to prepare liquids of 100 μg/mL in the high-dose group and 50 μg/mL in the middle-dose group

2.2 Experimental method

3T6 cells in the logarithmic growth phase were inoculated into 96-well plates at a concentration of 1×10 ⁴ /mL, a total of 80 wells, 200 μL per well, 200 μL of DEME medium was added to each well, and the 96-well plate was placed at 37°C for 5 Incubate for 24 h in a cell culture incubator with % CO ₂ . After 24 hours, the 96-well plate was divided into 4 groups, namely blank group, high-dose group, middle-dose group and low-dose group, with 20 wells in each group, and 100 μL of the experimental drug was added to each well, and PBS buffer was added to the blank group. After cultivating for 24 hours, use the MTT method to measure the absorbance value of each well at 490nm, calculate and determine the influence of the experimental drug on the proliferation of 3T6 cells, and calculate the proliferation-promoting rate. The experimental results are shown in Table 2, wherein

Proliferation rate=(OD of experimental group-OD of blank group)/OD of experimental group×100%.

2.3 Test results

Table 2. Effects of experimental drugs on pruritus in mice induced by 4-aminopyridine

Note: Compared with blank group: *P<0.05; **P<0.01.

Comparative example 1 is: weigh p-proanthocyanidin, chlorogenic acid, and lidocaine according to the ratio of 8:1:0.5, and use PBS solution to prepare 100 μg/mL liquid medicine respectively

Comparative Example 2: Weigh p-hydroxybenzonitrile, proanthocyanidin, and lidocaine according to the ratio of 3:8:0.5, and use PBS solution to prepare 100 μg/mL liquid medicine respectively

The experimental results in table 2 show that the pharmaceutical composition of the present invention in high and medium doses all shows a certain effect of promoting the proliferation of mouse skin fibroblasts. Fibroblasts proliferate, induce tissue fibrosis, and enhance tissue tension and strength effects.

Claims (10)

1. A pharmaceutical composition for the treatment of hernia in children, characterized in that the pharmaceutical composition comprises p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid, local anesthetic and pharmaceutically acceptable adjuvants. 2. the pharmaceutical composition for the treatment of infantile hernia according to claim 1, is characterized in that, the weight ratio of described p-hydroxybenzonitrile, proanthocyanidin, chlorogenic acid, local anesthetic is 1-5:5-10:1- 5:0.5-2, preferably 2-3:6-8:1-2:0.5-1, more preferably 3:8:1:0.5. 3. the pharmaceutical composition for the treatment of infantile hernia according to claim 1 and 2, is characterized in that, described local anesthetic is selected from: lidocaine, procaine, bupivacaine or ropivacaine, more Lidocaine is preferred. 4. The pharmaceutical composition for treating infantile hernia according to any one of claims 1-3, characterized in that, the pharmaceutical composition comprises 3 parts of p-hydroxybenzonitrile, 8 parts of proanthocyanidins, 1 part of chlorogenic acid, lidocaine Caine 0.5 parts and pharmaceutically acceptable auxiliary materials. 5. The pharmaceutical composition for treating hernia in children according to any one of claims 1-4, characterized in that, the pharmaceutical composition is a local preparation or an injection preparation. 6. the pharmaceutical composition for the treatment of infantile hernia according to claim 5, is characterized in that, described local preparation is selected from ointment, spray, is preferably ointment, and described injection preparation is injection or lyophilized powder injection. 7. the pharmaceutical composition for the treatment of infantile hernia according to claim 5 or 6, is characterized in that, also comprises penetration enhancer, preservative in the described topical preparation, preferably, described penetration enhancer is urea, described The preservative is paraben. 8. according to the pharmaceutical composition for the treatment of infantile hernia described in any one of claim 1-7, it is characterized in that, the content of active ingredient p-hydroxyphenylacetonitrile, proanthocyanidin, chlorogenic acid and local anesthetic in the described pharmaceutical composition is The total weight of the pharmaceutical composition is 1-90%, preferably 5-30%, more preferably 10-20%, most preferably 15%. 9. The use of p-hydroxybenzonitrile, proanthocyanidins, chlorogenic acid and local anesthetic in the preparation of a pharmaceutical composition for treating hernia in children. 10. The use according to claim 9, wherein the local anesthetic is selected from the group consisting of lidocaine, procaine, bupivacaine or ropivacaine, more preferably lidocaine.